Vaxart (STU:NB11) Long-Term Debt : €0.00 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Vaxart Long-Term Debt?

Vaxart's Long-Term Debt for the quarter that ended in Mar. 2024 was €0.00 Mil.

Vaxart Long-Term Debt Historical Data

The historical data trend for Vaxart's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxart Long-Term Debt Chart

Vaxart Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

Vaxart Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Vaxart (STU:NB11) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Vaxart Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Vaxart's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxart (STU:NB11) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (STU:NB11) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

VXRT:USA NB11:Germany

Address

170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.vaxart.com

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Vaxart (STU:NB11) Headlines

No Headlines